As our molecular biology tool set expands and becomes more sophisticated, the dream of bringing immuno-oncology approaches to the clinic is rapidly becoming a reality. But there are still some roadblocks on the way. Current methods for screening constructs for efficacy, such as the chromium release assay for cell-mediated cytotoxicity assays, are time-consuming, semi-quantitative, and only provide information on a single aspect of the biology.
With high-throughput sample processing and analysis, and the ability to simultaneously collect data on multiple parameters, the iQue Screener is transforming immuno-oncology development.